臨床泌尿器科72巻7号

2018年06月発行

特集 エキスパートが本音で語る! 膀胱癌診療の最前線

〈膀胱癌治療の最前線〉

膀胱癌に対するPD-1/PD-L1抗体治療

著者： 後藤駿介¹ 玉田耕治¹

所属機関： ¹山口大学大学院医学系研究科免疫学

ページ範囲：P.561 - P.564

文献概要

▶ポイント

・2017年12月に進行膀胱癌の二次治療として抗PD-1抗体ペムブロリズマブが承認された．

・シスプラチン既治療進行膀胱癌に対するペムブロリズマブの生存延長効果は腫瘍細胞上のPD-L1発現に依存しなかった．

・今後，抗PD-1/PD-L1抗体は進行膀胱癌に対する一次治療，術前後補助療法，化学療法との併用療法などへと適応拡大していく可能性がある．

参考文献

1） Bellmunt J, Powles T and Vogelzang NJ : A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer : The future is now. Cancer Treat Rev 54 : 58─67, 2017

2） Heymach J, Krilov L, Alberg A, et al : Clinical Cancer Advances 2018 : Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 36 : 1020─1044, 2018

3） Plimack ER, Bellmunt J, Gupta S, et al : Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer （KEYNOTE-012） : a non-randomised, open-label, phase 1b study. Lancet Oncol 18 : 212─220, 2017

4） Keir ME, Butte MJ, Freeman GJ, et al : PD-1 and its ligands in tolerance and immunity. Annual Rev Immunol 26 : 677─704, 2008

5） Adachi K and Tamada K : Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci 106 : 945─950, 2015

6） Bellmunt J, de Wit R, Vaughn DJ, et al : Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 376 : 1015─1026, 2017

7） Balar A, Bellmunt J, O'Donnell PH, et al : Pembrolizumab （pembro） as first-line therapy for advanced/unresectable or metastatic urothelial cancer : Preliminary results from the phase 2 KEYNOTE-052 study. Ann Oncol 27 : vi552─vi587, 2016

8） Balar AV, Castellano D, O'Donnell PH, et al : First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer （KEYNOTE-052） : a multicentre, single-arm, phase 2 study. Lancet Oncol 18 : 1483─1492, 2017

9） Balar AV, Galsky MD, Rosenberg JE, et al : Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma : a single-arm, multicentre, phase 2 trial. Lancet 389 : 67─76, 2017

10） Rosenberg JE, Hoffman-Censits J, Powles T, et al : Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy : a single-arm, multicentre, phase 2 trial. Lancet 387 : 1909─1920, 2016

11） Sharma P, Retz M, Siefker-Radtke A, et al : Nivolumab in metastatic urothelial carcinoma after platinum therapy （CheckMate 275） : a multicentre, single-arm, phase 2 trial. Lancet Oncol 18 : 312─322, 2017

12） Patel MR, Ellerton J, Infante JR, et al : Avelumab in metastatic urothelial carcinoma after platinum failure （JAVELIN Solid Tumor） : pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 19 : 51─64, 2018

13） Massard C, Gordon MS, Sharma S, et al : Safety and Efficacy of Durvalumab （MEDI4736）, an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol 34 : 3119─3125, 2016

14） Powles T, Duran I, van der Heijden MS, et al : Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma （IMvigor211） : a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391 : 748─757, 2018

15） Massari F, Di Nunno V, Cubelli M, et al : Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treat Rev 64 : 11─20, 2018

16） Powles T, Smith K, Stenzl A, et al : Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. Eur Urol 72 : 477─481, 2017